Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Abstract 651: Safety and efficacy of pembrolizumab plus personal dendritic cell vaccines in elderly patients with metastatic melanoma

Chaitali S. Nangia, Katrina L. Lopez, Gabriel I. Nistor, Robert O. Dillman

Cancer Res (2025) 85 (8_Supplement_1): 651.

https://doi.org/10.1158/1538-7445.AM2025-651

Published: 21 April 2025

View article titled, Abstract 651: Safety and efficacy of pembrolizumab plus personal dendritic cell vaccines in elderly patients with metastatic melanoma

Journal Articles

Abstract 6519: Dendritic cell vaccine cell numbers and survival in patients with primary glioblastoma

Robert O. Dillman, Gabriel I. Nistor, Krystal Godding, Rockelle Robles, Hans S. Keirstead

Cancer Res (2024) 84 (6_Supplement): 6519.

https://doi.org/10.1158/1538-7445.AM2024-6519

Published: 22 March 2024

View article titled, Abstract 6519: Dendritic cell vaccine cell numbers and survival in patients with primary glioblastoma

Journal Articles

Abstract CT571: Plasma proteomic markers prognostic or predictive for survival of patients with newly diagnosed glioblastoma who were treated in a phase II trial with standard care and the addition of the novel patient-specific dendritic cell vaccine AV-GBM-1

Daniela A. Bota, David E. Piccioni, Christopher M. Duma, Renato V. LaRoca, Santosh Kesari, Mehrdad Abedi, Robert D. Aiken, Aleksandra J. Poole, Gabriel I. Nistor, Robert O. Dillman

Cancer Res (2022) 82 (12_Supplement): CT571.

https://doi.org/10.1158/1538-7445.AM2022-CT571

Published: 15 June 2022

View article titled, Abstract CT571: Plasma proteomic markers prognostic or predictive for survival of patients with newly diagnosed glioblastoma who were treated in a phase II trial with standard care and the addition of the novel patient-specific dendritic cell vaccine AV-GBM-1

Journal Articles

Abstract CT189: Patient-specific dendritic cell vaccines with tumor antigens from self-renewing autologous tumor cells in the treatment of primary advanced ovarian cancer: A multi-institutional phase II clinical trial

Lisa N. Abaid, Bradley R. Corr, James R. Mason, Richard L. Friedman, Ramez N. Eskander, Candace Hsieh, Chris J. Langford, Krystal Carta, Adrienne M. Wang, James A. Langford, Gabriel I. Nistor, Robert O. Dillman

Cancer Res (2020) 80 (16_Supplement): CT189.

https://doi.org/10.1158/1538-7445.AM2020-CT189

Published: 15 August 2020

View article titled, Abstract CT189: Patient-specific dendritic cell vaccines with tumor antigens from self-renewing autologous tumor cells in the treatment of primary advanced ovarian cancer: A multi-institutional phase II clinical trial

Journal Articles

Abstract CT182: Adjunctive treatment of primary glioblastoma with patient-specific dendritic cell vaccines pulsed with antigens from self-renewing autologous tumor cells: A phase II trial

Daniella A. Bota, Christopher M. Duma, Santosh Kesari, David E. Piccioni, Renato V. LaRocca, Robert T. O'Donnell, Robert D. Aiken, Jose A. Carrillo, Candace Hsieh, Chris J. Langford, Krystal Carta, Adrienne M. Wang, James A. Langford, Thomas H. Taylor, Gabriel I. Nistor, Robert O. Dillman

Cancer Res (2020) 80 (16_Supplement): CT182.

https://doi.org/10.1158/1538-7445.AM2020-CT182

Published: 15 August 2020

View article titled, Abstract CT182: Adjunctive treatment of primary glioblastoma with patient-specific dendritic cell vaccines pulsed with antigens from self-renewing autologous tumor cells: A phase II trial

Journal Articles

Abstract 1357: Serum levels of programmed cell death molecule-1 (PD-1) as a biomarker in metastatic melanoma patients randomized for treatment with autologous dendritic cell or tumor cell vaccines

Robert O. Dillman, Gabriel I. Nistor, Aleksandra J. Poole, Andrew N. Cornforth

Cancer Res (2019) 79 (13_Supplement): 1357.

https://doi.org/10.1158/1538-7445.AM2019-1357

Published: 01 July 2019

View article titled, Abstract 1357: Serum levels of programmed cell death molecule-1 (PD-1) as a biomarker in metastatic melanoma patients randomized for treatment with autologous dendritic cell or tumor cell vaccines

Journal Articles

Abstract CT105: Randomized trial of dendritic vs tumor cell patient-specific vaccines: 5-year analysis

Robert O. Dillman, Edward F. McClay, Thomas T. Amatruda, Carol DePriest, Denysha J. Carbonell, Andrew N. Cornforth

Cancer Res (2016) 76 (14_Supplement): CT105.

https://doi.org/10.1158/1538-7445.AM2016-CT105

Published: 15 July 2016

View article titled, Abstract CT105: Randomized trial of dendritic vs tumor cell patient-specific vaccines: 5-year analysis

Journal Articles

Abstract 4845: Microarray analysis of melanoma autologous tumor cell lines used as the source of tumor associated antigens in patient-specific dendritic cell immunotherapy phase II trial in patients with metastatic melanoma

Andrew N. Cornforth, Gary Fogel, Denysha Carbonell, Robert O. Dillman

Cancer Res (2015) 75 (15_Supplement): 4845.

https://doi.org/10.1158/1538-7445.AM2015-4845

Published: 01 August 2015

View article titled, Abstract 4845: Microarray analysis of melanoma autologous tumor cell lines used as the source of tumor associated antigens in patient-specific dendritic cell immunotherapy phase II trial in patients with metastatic melanoma

Journal Articles

Abstract 197: 5-year survival for patients with metastatic melanoma who had no evidence of disease at time of treatment with patient specific tumor stem cell vaccines

Robert O. Dillman, Carol DePriest, Robine Ellis, Cristina de Leon

Cancer Res (2014) 74 (19_Supplement): 197.

https://doi.org/10.1158/1538-7445.AM2014-197

Published: 01 October 2014

View article titled, Abstract 197: 5-year survival for patients with metastatic melanoma who had no evidence of disease at time of treatment with patient specific tumor stem cell vaccines

Journal Articles

Abstract P3-14-02: Should patients with comedo ductal carcinoma in situ (DCIS) be managed as if they have locally invasive breast cancer?

Robert O Dillman, Stephanie E McClure, Francis S Heinemann

Cancer Res (2012) 72 (24_Supplement): P3-14-02.

https://doi.org/10.1158/0008-5472.SABCS12-P3-14-02

Published: 15 December 2012

View article titled, Abstract P3-14-02: Should patients with comedo ductal carcinoma in situ (DCIS) be managed as if they have locally invasive breast cancer?

Journal Articles

Abstract 3703: Randomized trial of autologous dendritic cell vs tumor cell vaccines in patients with metastatic melanoma

Robert O. Dillman, Andrew N. Cornforth, Carol DePriest, Edward C. McClay, Thomas T. Amatruda, Denysha Carbonell, Cristina DeLeon, Cheryl Mayorga, Robin Ellis, James Cubellis

Cancer Res (2012) 72 (8_Supplement): 3703.

https://doi.org/10.1158/1538-7445.AM2012-3703

Published: 15 April 2012

View article titled, Abstract 3703: Randomized trial of autologous dendritic cell vs tumor cell vaccines in patients with metastatic melanoma

Journal Articles

Abstract 768: Lymphokine activated killer cell conditioned media induces monocytes to differentiate into a dendritic cell-like/activated monocyte phenotype with cytotoxic potential against glioblastoma

Andrew N. Cornforth, Gregory Lee, Eric Fan, Abner Fowler, Jessica Alldredge, Denysha Carbonell, Robert O. Dillman

Cancer Res (2011) 71 (8_Supplement): 768.

https://doi.org/10.1158/1538-7445.AM2011-768

Published: 15 April 2011

View article titled, Abstract 768: Lymphokine activated killer cell conditioned media induces monocytes to differentiate into a dendritic cell-like/activated monocyte phenotype with cytotoxic potential against glioblastoma

Journal Articles

Abstract 5027: Steadily improving survival in lung cancer

Robert O. Dillman, Stephanie E. McClure, Douglas R. Zusman, Louis A. VanderMolen, Khosrow Mahdavi, Russell A. Hafer, Craig A. Cox, Colin I. Joyo, Neil M. Barth

Cancer Res (2011) 71 (8_Supplement): 5027.

https://doi.org/10.1158/1538-7445.AM2011-5027

Published: 15 April 2011

View article titled, Abstract 5027: Steadily improving survival in lung cancer

Journal Articles

Abstract 5537: Surgical resection and survival in octagenarians and younger age cohorts of patients diagnosed with non-small cell lung cancer.

Robert O Dillman, Douglas R Zusman, Colin I Joyo

Cancer Res (2008) 68 (9_Supplement): 5537.

https://doi.org/10.1158/1538-7445.AM2008-5537

Published: 15 May 2008

View article titled, Abstract 5537: Surgical resection and survival in octagenarians and younger age cohorts of patients diagnosed with non-small cell lung cancer.

Journal Articles

Serum S100B levels predict overall survival in a dendritic cell based vaccine study for melanoma patients

Patric M. Schiltz, Catharina M. Korse, James Cubellis, Gregory J. Lee, Gijsbert C. De Gast, Robert O. Dillman

Cancer Res (2006) 66 (8_Supplement): 678.

Published: 15 April 2006

View article titled, Serum S100B levels predict overall survival in a dendritic cell based vaccine study for melanoma patients

Journal Articles

Dendritic cells loaded with proliferating autologous tumor cells as patient-specific vaccines in recurrent or metastatic melanoma and renal cell cancer

Robert O. Dillman, Senthamil R. Selvan, Patric M. Schiltz, Kanoelani Allen, Cheryl Peterson, Cristina De Leon, Carol Depriest, Andrea Beatty, Linda D. Beutel

Cancer Res (2006) 66 (8_Supplement): 678.

Published: 15 April 2006

View article titled, Dendritic cells loaded with proliferating autologous tumor cells as patient-specific vaccines in recurrent or metastatic melanoma and renal cell cancer

Journal Articles

Melanoma patients treated with an autologous dendritic cell vaccine demonstrate tumor reactive antibodies

Sarah L. Hendry, Patric M. Schiltz, Robert O. Dillman

Cancer Res (2005) 65 (9_Supplement): 815.

Published: 01 May 2005

View article titled, Melanoma patients treated with an autologous dendritic cell vaccine demonstrate tumor reactive antibodies

Journal Articles

Improved survival for patients with invasive cancer after opening a comprehensive cancer center: comparisons to intramural and extramural benchmarks

Robert O. Dillman, Sherri D. Chico

Cancer Res (2005) 65 (9_Supplement): 991.

Published: 01 May 2005

View article titled, Improved survival for patients with invasive cancer after opening a comprehensive cancer center: comparisons to intramural and extramural benchmarks

Journal Articles

Immunemonitoring of patients receiving autologous tumor cell-based vaccine: Simple whole blood assay

Senthamil S. Selvan, Abner W. Fowler, Kodumudi S. Venkateswaran, Viswanathan V. Krishnan, Robert O. Dillman

Cancer Res (2005) 65 (9_Supplement): 363–364.

Published: 01 May 2005

View article titled, Immunemonitoring of patients receiving autologous tumor cell-based vaccine: Simple whole blood assay

Journal Articles

Protein array evaluation of serum cytokines in metastatic melanoma patients before and after treatment with a dendritic cell based vaccine

Patric M. Schiltz, Robert O. Dillman

Cancer Res (2005) 65 (9_Supplement): 364.

Published: 01 May 2005

View article titled, Protein array evaluation of serum cytokines in metastatic melanoma patients before and after treatment with a dendritic cell based vaccine

Update search

NARROW

Format

Journal

Article Type

Issue Section

Date

Availability

Abstract 651: Safety and efficacy of pembrolizumab plus personal dendritic cell vaccines in elderly patients with metastatic melanoma

Abstract 6519: Dendritic cell vaccine cell numbers and survival in patients with primary glioblastoma

Abstract CT571: Plasma proteomic markers prognostic or predictive for survival of patients with newly diagnosed glioblastoma who were treated in a phase II trial with standard care and the addition of the novel patient-specific dendritic cell vaccine AV-GBM-1

Abstract CT189: Patient-specific dendritic cell vaccines with tumor antigens from self-renewing autologous tumor cells in the treatment of primary advanced ovarian cancer: A multi-institutional phase II clinical trial

Abstract CT182: Adjunctive treatment of primary glioblastoma with patient-specific dendritic cell vaccines pulsed with antigens from self-renewing autologous tumor cells: A phase II trial

Abstract 1357: Serum levels of programmed cell death molecule-1 (PD-1) as a biomarker in metastatic melanoma patients randomized for treatment with autologous dendritic cell or tumor cell vaccines

Abstract CT105: Randomized trial of dendritic vs tumor cell patient-specific vaccines: 5-year analysis

Abstract 4845: Microarray analysis of melanoma autologous tumor cell lines used as the source of tumor associated antigens in patient-specific dendritic cell immunotherapy phase II trial in patients with metastatic melanoma

Abstract 197: 5-year survival for patients with metastatic melanoma who had no evidence of disease at time of treatment with patient specific tumor stem cell vaccines

Abstract P3-14-02: Should patients with comedo ductal carcinoma in situ (DCIS) be managed as if they have locally invasive breast cancer?

Abstract 3703: Randomized trial of autologous dendritic cell vs tumor cell vaccines in patients with metastatic melanoma

Abstract 768: Lymphokine activated killer cell conditioned media induces monocytes to differentiate into a dendritic cell-like/activated monocyte phenotype with cytotoxic potential against glioblastoma

Abstract 5027: Steadily improving survival in lung cancer

Abstract 5537: Surgical resection and survival in octagenarians and younger age cohorts of patients diagnosed with non-small cell lung cancer.

Serum S100B levels predict overall survival in a dendritic cell based vaccine study for melanoma patients

Dendritic cells loaded with proliferating autologous tumor cells as patient-specific vaccines in recurrent or metastatic melanoma and renal cell cancer

Melanoma patients treated with an autologous dendritic cell vaccine demonstrate tumor reactive antibodies

Improved survival for patients with invasive cancer after opening a comprehensive cancer center: comparisons to intramural and extramural benchmarks

Immunemonitoring of patients receiving autologous tumor cell-based vaccine: Simple whole blood assay

Protein array evaluation of serum cytokines in metastatic melanoma patients before and after treatment with a dendritic cell based vaccine

Email alerts

AACR Journals

Resources

AACR Journals
on Social Media

Update search

Email alerts

AACR Journals

Resources

AACR Journals on Social Media

This Feature Is Available To Subscribers Only

AACR Journals
on Social Media